SBIR/STTR Research Award

Development of a Mitochondrial Disease Profiling Array

Award identifier ace33a33e05052e25333452fdee92355caf2c66d30313cdac8fe7fd77ee28d5cAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$178,265

Program and phase

SBIR · Phase I

Award year

2005

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
GENEPROTECH,INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
PHS2005-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Mitochondrial disease caused by point mutations in mitochondrial DMA (mtDNA) can be a formidable diagnostic challenge. Because clinical presentation can be variable, multisystemic, and mimic many other neurological disorders, ruling out an mtDNA etiology is difficult in patients with suspected myopathies or encephalopathies. DMA microarrays would seem to provide an ideal format for screening patient samples for the approximately200 mtDNA point mutations known or suspected to cause mitochondrial disease (Figure 1). When fabricated from conventional DNA oligonucleotides, however, microarrays often have inadequate power to discriminate, by hybridization, between mutant and wild-type DNAs that differ by a single base mismatch. This problem is aggravated for mtDNA mutations because they are present in most patients as a mixture of wild-type and mutant molecules - often as low as 10% in easily sampled material like peripheral blood. Oligonucleotides synthesized from Locked Nucleic Acid (LNA) nucleotides show much better mismatch detection. LNA-containing oligonucleotides in duplex with normal DNA have a remarkable combination of both high thermal stability (Tm) and enhanced Tm - i.e., the melting temperature difference between a perfect match and single base mismatch. Consequently, short probes (7-9 nt in length) can be used in arrays to maximize discriminatory power between mutant and wild-type DNAs while retaining efficient hybridization and, thus, sensitivity. Here, we propose to develop an array fabricated from LNA oligonucleotides for the detection of all 27 confirmed pathogenic point mutations in mtDNA. Its sensitivity for the detection of mtDNA mutations will be measured in samples containing a mixture of wild-type and mutant molecules. These studies will provide proof of principle for the successful design of an inclusive array to detect all reported pathogenic mtDNA mutations. As new ones are discovered, updated versions would be easy to generate. Towards this goal, the Specific Aims of this proposal are: Specific Aim 1: To develop capture probe pairs towards a set of 27 different mtDNA mutations. Specific Aim 2: To determine the performance of an optimized array to detect mtDNA mutations at varying frequencies.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.